New hope for hard-to-treat breast cancer: triple therapy trial launches
NCT ID NCT07015853
First seen May 02, 2026 · Last updated May 02, 2026
Summary
This study tests a combination of three treatments—an immunotherapy drug (pembrolizumab), a targeted drug (axatilimab), and radiation—to see if they can shrink or control metastatic triple-negative breast cancer in people who have already tried immunotherapy. About 34 adults with at least two measurable tumors will join. The goal is to improve response in non-irradiated tumors and track side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
Conditions
Explore the condition pages connected to this study.